Company research / DNLI

Denali Therapeutics Inc. (DNLI)

CIK 0001714899 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Denali Therapeutics Inc. reported revenue of $0.

Key ratios (year ended 2025-12-31)

-50.6%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 4 · 2026-09-04

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.